Arjun Agarwal Sells 560 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 560 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60. Following the completion of the transaction, the senior vice president owned 14,752 shares of the company’s stock, valued at approximately $1,411,913.92. The trade was a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Trading Up 1.5%

Shares of ORKA stock opened at $93.55 on Thursday. The company has a market capitalization of $6.19 billion, a price-to-earnings ratio of -46.08 and a beta of -0.34. Oruka Therapeutics, Inc. has a 1-year low of $14.89 and a 1-year high of $115.51. The stock’s fifty day simple moving average is $96.05 and its 200-day simple moving average is $73.20.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Investors are watching the upcoming EVERLAST-A data covering more than 28 weeks of treatment in psoriasis. Positive durability or efficacy results for ORKA-001 could strengthen confidence in Oruka’s long-acting antibody platform and provide an important near-term catalyst for the stock. EVERLAST-A data catalyst article
• Positive Sentiment: Analyst sentiment remains favorable, with ten Buy ratings versus one Sell rating and a consensus price target of approximately $133, above the recent trading range. Recent targets from firms including BTIG, Wedbush, Mizuho and HC Wainwright range from $120 to $165, supporting the bullish view of Oruka’s pipeline. Oruka analyst ratings
• Neutral Sentiment: Company insiders reported multiple stock sales: CEO Lawrence Klein sold 2,452 shares, SVP Arjun Agarwal sold 10,019 shares across two recent transactions, and Joana Goncalves sold 7,947 shares. The transactions were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding obligations from vested equity awards, making them less indicative of negative views than discretionary selling. Oruka insider sales report
• Negative Sentiment: Oruka remains a loss-making clinical-stage biotechnology company. Its latest quarterly loss of $0.55 per share was wider than the expected $0.51 loss, and analysts anticipate a full-year loss of about $2.42 per share. The valuation therefore remains highly dependent on clinical execution and future trial results.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently modified their holdings of ORKA. Nykredit A S acquired a new position in shares of Oruka Therapeutics in the second quarter valued at $29,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at $67,000. Orion Capital Management LLC bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $91,000. Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 178.5% during the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after acquiring an additional 2,033 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Oruka Therapeutics by 119.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock valued at $156,000 after acquiring an additional 1,736 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

Analyst Ratings Changes

ORKA has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. UBS Group upped their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Piper Sandler reissued an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.